凤凰网港股|BioNTech SE(BNTX)大涨逾10%，报432美元。此前，BioNTech SE公布了2021年第二季度财务业绩。数据显示，公司Q2总营收53.09亿欧元，市场预期为34.99亿欧元，上年同期为4170万欧元，同比增长超126倍;净利润27.87亿欧元，上年同期为亏损8830万欧元。每股基本收益为11.42欧元，上年同期为亏损0.38欧元;摊薄后每股收益为10.77欧元，上年同期为亏损0.38欧元。营业利润为41.98亿欧元，上年同期为亏损8090万欧元。研发支出2.01亿欧元，上年同期为9520万欧元;销售及营销费用1330万欧元，上年同期为300万欧元。
BioNTech首席执行官兼联合创始人Ugur Sahin表示，"我们和合作伙伴辉瑞(PFE)公司已经突破了全球COVID-19疫苗剂量的10亿大关。我们很自豪在仅仅六个月后就达到了这个伟大的里程碑，并且用我们专有的mRNA技术为人们带来了改变。为了应对当前的大流行，我们正在向全球100多个国家和地区扩大COVID-19疫苗的供应，包括增加对低收入和中等收入国家的访问，"。"同时，我们进一步开发了肿瘤学管道，包括最近启动的两个 FixVac 程序的随机阶段2试验。我们能够跨各种技术平台推进多个肿瘤学计划，这些平台现在进入后期测试阶段，为未来几年向市场推出一系列产品候选产品提供了潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments